Wed. 8 May 2024, 4:56pm ET
Benzinga
News, Guidance
- HEPLISAV-B net product revenue between approximately $265 - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany
- HEPLISAV-B gross margin of approximately 80%